Leadership

This year marks the 30th anniversary of the NIH revitalization act that required women and minorities to be included in clinical research in the US. Putting that into perspective, we have only really been collecting data at scale on women and minorities since the movie Jurassic Park was launched. If we want more people to participate in clinical trials, it is time to get real about reducing the burden of research on volunteers.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.

Across the health care industry, the increasing numbers of ethics violations, data breaches and reputational challenges reflect the growing magnitude and prevalence of compliance failures.

In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.

Michelle Werner, CEO of Alltrna, sat down with In Vivo to discuss rare disease as an increasingly important area of study, innovation in the space and how the emerging biotech hopes to impact the treatment landscape.

Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead. 

Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder. 

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

LGBTQ networking group OUTbio has gone from strength to strength since it was founded in 2015, from a small event attended by a handful of executives in Boston to a registered non-profit with affiliated groups across the US alongside international branches.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.

Jacqueline Henderson was appointed president, Johnson & Johnson Vision, EMEA, in April, as part of a restructuring of senior regional roles. Now overseeing this most culturally diverse of territories for both Vision Care and Surgical Vision, she explains the rationale for the internal realignment and where Johnson & Johnson Vision goes next.

CEO Scott Braunstein, who took leadership of Marinus in 2019 following clinical trial setbacks, believes the company is on a route to success with its ganaxolone program, targeting chronic use and hospital markets. 

Christoffer Ekström, one of In Vivo's 2023 Rising Leaders, spoke about the challenges a start-up founder faces, the importance of never giving up and how one should always learn from the past.